D. M. Goldenberg, F. Deland, E. Kim, S. Bennett, F. J. Primus et al., Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning, N Engl J Med, vol.298, pp.1384-1390, 1978.

A. M. Wu, Antibodies and antimatter: the resurgence of immuno-PET, J Nucl Med Off Publ Soc Nucl Med, vol.50, pp.2-5, 2009.

O. C. Boerman and W. Oyen, Immuno-PET of cancer: a revival of antibody imaging, J Nucl Med Off Publ Soc Nucl Med, vol.52, pp.1171-1173, 2011.

C. Bailly, P. Cléry, A. Faivre-chauvet, M. Bourgeois, F. Guérard et al., Immuno-PET for clinical theranostic approaches, Int J Mol Sci, vol.18, p.57, 2016.
URL : https://hal.archives-ouvertes.fr/in2p3-01951323

F. Kraeber-bodere, C. Bailly, M. Chérel, and J. Chatal, ImmunoPET to help stratify patients for targeted therapies and to improve drug development, Eur J Nucl Med Mol Imaging, vol.43, pp.2166-2174, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01809742

A. Machens, U. Schneyer, H. Holzhausen, and H. Dralle, Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level, J Clin Endocrinol Metab, vol.90, pp.2029-2063, 2005.

S. A. Wells, S. L. Asa, H. Dralle, R. Elisei, D. B. Evans et al., Revised American thyroid association guidelines for the management of medullary thyroid carcinoma, Thyroid Off J Am Thyroid Assoc, vol.25, pp.567-610, 2015.

M. Luster, W. Karges, K. Zeich, S. Pauls, F. A. Verburg et al., Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma, Thyroid Off J Am Thyroid Assoc, vol.20, pp.527-560, 2010.

S. Kauhanen, C. Schalin-jäntti, M. Seppänen, S. Kajander, S. Virtanen et al., Complementary roles of 18 F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer, J Nucl Med Off Publ Soc Nucl Med, vol.52, pp.1855-63, 2011.

A. Oudoux, P. Salaun, C. Bournaud, L. Campion, C. Ansquer et al., Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigentargeted radioimmunotherapy, J Clin Endocrinol Metab, vol.92, pp.4590-4597, 2007.

H. Verbeek, J. Plukker, K. P. Koopmans, J. De-groot, R. Hofstra et al., Clinical relevance of 18F-FDG PET and 18F-DOPA PET in recurrent medullary thyroid carcinoma, J Nucl Med Off Publ Soc Nucl Med, vol.53, pp.1863-71, 2012.

P. Peltier, C. Curtet, J. F. Chatal, L. Doussal, J. M. Daniel et al., Radioimmunodetection of medullary thyroid cancer using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer, J Nucl Med Off Publ Soc Nucl Med, vol.34, pp.1267-73, 1993.

J. Barbet, P. Peltier, S. Bardet, J. P. Vuillez, I. Bachelot et al., Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody, J Nucl Med Off Publ Soc Nucl Med, vol.39, pp.1172-1180, 1998.

P. Salaun, L. Campion, C. Bournaud, A. Faivre-chauvet, J. Vuillez et al., Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement, J Nucl Med Off Publ Soc Nucl Med, vol.53, pp.1185-92, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00932253

R. P. Baum, V. Prasad, D. Müller, C. Schuchardt, A. Orlova et al., Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111 In-or 68 Ga-labeled affibody molecules, J Nucl Med Off Publ Soc Nucl Med, vol.51, pp.892-899, 2010.

K. Tamura, H. Kurihara, K. Yonemori, H. Tsuda, J. Suzuki et al., 64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer, J Nucl Med Off Publ Soc Nucl Med, vol.54, pp.1869-75, 2013.

F. Bensch, E. L. Van-der-veen, M. N. Lub-de-hooge, A. Jorritsma-smit, R. Boellaard et al., 89 Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer, Nat Med, vol.24, pp.1852-1860, 2018.

C. M. Van-rij, S. Lütje, C. Frielink, R. M. Sharkey, D. M. Goldenberg et al., Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody, Eur J Nucl Med Mol Imaging, vol.40, pp.1377-83, 2013.

M. Altai, R. Membreno, B. Cook, V. Tolmachev, and B. M. Zeglis, Pretargeted imaging and therapy, J Nucl Med Off Publ Soc Nucl Med, vol.58, pp.1553-1562, 2017.

R. Schoffelen, R. M. Sharkey, D. M. Goldenberg, G. Franssen, W. J. Mcbride et al., Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a 68 Ga-and 18 F-labeled hapten peptide in mice with human tumor xenografts, Mol Cancer Ther, vol.9, pp.1019-1046, 2010.

W. J. Mcbride, R. M. Sharkey, H. Karacay, D. Souza, C. A. Rossi et al., A novel method of 18F radiolabeling for PET, J Nucl Med Off Publ Soc Nucl Med, vol.50, pp.991-999, 2009.

E. A. Rossi, D. M. Goldenberg, T. M. Cardillo, W. J. Mcbride, R. M. Sharkey et al., Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting, Proc Natl Acad Sci, vol.103, pp.6841-6847, 2006.

W. J. Mcbride, P. Zanzonico, R. M. Sharkey, C. Norén, H. Karacay et al., Bispecific antibody pretargeting PET (immunoPET) with an 124 Ilabeled hapten-peptide, J Nucl Med Off Publ Soc Nucl Med, vol.47, pp.1678-88, 2006.

R. Schoffelen, O. C. Boerman, D. M. Goldenberg, R. M. Sharkey, C. Van-herpen et al., Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results, Br J Cancer, vol.109, pp.934-976, 2013.

R. Schoffelen, W. Woliner-van-der-weg, E. P. Visser, D. M. Goldenberg, R. M. Sharkey et al., Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer, Eur J Nucl Med Mol Imaging, vol.41, pp.1593-602, 2014.

F. Kraeber-bodéré, C. Rousseau, C. Bodet-milin, L. Ferrer, A. Faivre-chauvet et al., Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131 I-labeled bivalent hapten in a phase I optimization clinical trial, J Nucl Med Off Publ Soc Nucl Med, vol.47, pp.247-55, 2006.

C. Bodet-milin, L. Ferrer, A. Rauscher, D. Masson, L. Rbah-vidal et al., Pharmacokinetics and dosimetry studies for optimization of pretargeted radioimmunotherapy in CEA expressing advanced lung cancer patient, Front Med Lausanne, vol.2, p.84, 2015.

F. Foubert, S. Gouard, C. Saï-maurel, M. Chérel, A. Faivre-chauvet et al., Sensitivity of pretargeted immunoPET using 68 Ga-peptide to detect colonic carcinoma liver metastases in a murine xenograft model: comparison with 18FDG PET-CT, Oncotarget, vol.9, pp.27502-27515, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-01981491

C. Bodet-milin, A. Faivre-chauvet, T. Carlier, A. Rauscher, M. Bourgeois et al., Immuno-PET using anti-CEA bispecific antibody and 68 Ga-labeled peptide in metastatic medullary thyroid carcinoma: clinical optimization of the pretargeting parameters in a First-in Human trial, J Nucl Med Off Publ Soc Nucl Med, vol.57, pp.1505-1516, 2016.

C. Bodet-milin, C. Rousseau, C. Ansquer, A. Faivre-chauvet, A. Rauscher et al., High sensitivity of pretargeted immuno-PET using anti-carcinoembryonic antigen (CEA) bispecific antibody and Ga-68-labeled peptide in metastatic medullary thyroid carcinoma

, Eur J Nucl Med Mol Imaging, vol.41, pp.314-319

C. Rousseau, M. Campone, A. Rauscher, A. Faivre-chauvet, T. Carlier et al., Pretargeted immuno-PET with an anti-carcinoembryonic antigen (CEA) bispecific antibody (BsMAb) and a 68 Ga-labeled hapten-peptide compared to conventional imaging and FDG-PET in metastatic breast cancer patients (BC): First results, Cancer Res, vol.75, 2015.

Y. Touchefeu, C. Bailly, E. Frampas, T. Eugène, C. Rousseau et al., Pre-targeted immuno-PET with bispecific anti-CEA antibody and Gallium-68-labeled IMP-288 peptide for imaging of metastates from colorectal cancer, JFHOD Annual Meeting, 2019.

H. Honarvar, K. Westerlund, M. Altai, M. Sandström, A. Orlova et al., Feasibility of affibody molecule-based PNA-mediated radionuclide pretargeting of malignant tumors, Theranostics, vol.6, pp.93-103, 2016.

R. Rossin, P. R. Verkerk, S. M. Van-den-bosch, R. Vulders, I. Verel et al., In vivo chemistry for pretargeted tumor imaging in live mice, Angew Chem Int Ed Engl, vol.49, pp.3375-3383, 2010.